| Literature DB >> 11561682 |
M L Varterasian1, P A Pemberton, K Hulburd, D H Rodriguez, A Murgo, A M Al-Katib.
Abstract
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, is a protein kinase C (PKC) modulator which has shown both preclinical and clinical activity in lymphoid malignancies. We conducted a phase II trial of bryostatin 1 administered at a dose of 120 microg/m2 by 72-h continuous infusion every 2 weeks in patients with relapsed multiple myeloma. Treatment was well tolerated with myalgias constituting the primaray toxicity. There were no responses in nine evaluable patients. The preclinical anti-lymphoid activity is strong enough to support further exploration of bryostatin 1 in different schedules and in combination therapy for multiple myeloma.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11561682 DOI： 10.1023/a:1010676719178
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850